Licensing rights to commercialize Caerulomycin A

US based Nostrum Pharmaceuticals has obtained a worldwide licensing rights from Indian based Institute of Microbial Technology or IMTECH to develop and commercialise Caerulomycin A, and its proprietary derivatives and analogues for their novel indication and immuno-suppression. IMTECH is a constituent laboratory of the Council of Scientific and Industrial Research.